TY - JOUR
T1 - Immunotherapy against systemic fungal infections based on monoclonal antibodies
AU - Boniche, Camila
AU - Rossi, Suélen Andreia
AU - Kischkel, Brenda
AU - Barbalho, Filipe Vieira
AU - Moura, Ágata Nogueira D’Aurea
AU - Nosanchuk, Joshua D.
AU - Travassos, Luiz R.
AU - Taborda, Carlos Pelleschi
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/3
Y1 - 2020/3
N2 - The increasing incidence in systemic fungal infections in humans has increased focus for the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses are generally difficult to treat, as most occur in vulnerable individuals, with compromised innate and adaptive immune responses. Mortality rates in the setting of our current antifungal drugs remain excessively high. Moreover, systemic mycoses require prolonged durations of antifungal treatment and side effects frequently occur, particularly drug-induced liver and/or kidney injury. The use of monoclonal antibodies with or without concomitant administration of antifungal drugs emerges as a potentially efficient treatment modality to improve outcomes and reduce chemotherapy toxicities. In this review, we focus on the use of monoclonal antibodies with experimental evidence on the reduction of fungal burden and prolongation of survival in in vivo disease models. Presently, there are no licensed monoclonal antibodies for use in the treatment of systemic mycoses, although the potential of such a vaccine is very high as indicated by the substantial promising results from several experimental models.
AB - The increasing incidence in systemic fungal infections in humans has increased focus for the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses are generally difficult to treat, as most occur in vulnerable individuals, with compromised innate and adaptive immune responses. Mortality rates in the setting of our current antifungal drugs remain excessively high. Moreover, systemic mycoses require prolonged durations of antifungal treatment and side effects frequently occur, particularly drug-induced liver and/or kidney injury. The use of monoclonal antibodies with or without concomitant administration of antifungal drugs emerges as a potentially efficient treatment modality to improve outcomes and reduce chemotherapy toxicities. In this review, we focus on the use of monoclonal antibodies with experimental evidence on the reduction of fungal burden and prolongation of survival in in vivo disease models. Presently, there are no licensed monoclonal antibodies for use in the treatment of systemic mycoses, although the potential of such a vaccine is very high as indicated by the substantial promising results from several experimental models.
KW - Antifungal vaccines
KW - Immunotherapy
KW - Monoclonal antibodies
KW - Passive immunization
KW - Systemic fungal infections
KW - Therapeutic vaccines
UR - http://www.scopus.com/inward/record.url?scp=85081258714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081258714&partnerID=8YFLogxK
U2 - 10.3390/jof6010031
DO - 10.3390/jof6010031
M3 - Review article
AN - SCOPUS:85081258714
SN - 2309-608X
VL - 6
JO - Journal of Fungi
JF - Journal of Fungi
IS - 1
M1 - 31
ER -